James A. Lebovitz represents clients in securities transactions, mergers and acquisitions, strategic alliances and general corporate matters. He has extensive experience advising public and privately-held corporations in the life sciences, healthcare, financial and business services sectors, business development companies (BDCs) and other specialty finance companies, and investment banks in corporate transactions and financings. Having previously worked in-house as general counsel of a publicly-traded company, Mr. Lebovitz brings a particularly strong commercial perspective when representing clients in transactions. In fact, Chambers USA, a referral guide to leading lawyers in the United States, which consistently recognizes Mr. Lebovitz as a leading lawyer for corporate/M&A and private equity as well as capital markets, described him as a "collaborative, thoughtful, commercial lawyer" who “is down to earth and stands out as a leader" and “knows just how to get the deal done.” Mr. Lebovitz is also recognized as a leading lawyer for corporate law, securities law, mergers and acquisitions law, leveraged buyouts and private equity law, and biotechnology law in The Best Lawyers in America, is listed as a "Life Sciences Star" in LMG Life Sciences, and has recently been selected as a leading lawyer for M&A in the IFLR1000. In addition, Mr. Lebovitz has also been recognized for his extensive corporate finance and mergers and acquisitions experience in The Legal 500 (U.S.), which has praised him for his “unique combination of nuts and bolts wisdom, as well as experienced counsel in complicated matters” and has described him as "exceptional."
Mr. Lebovitz is the chair of Dechert’s firm-wide lawyer hiring committee and previously served as partner responsible for associate development. From 2000 to 2005, he served as chair of the firm’s business and technology practice group.
Mr. Lebovitz joined Dechert in July 1999 as a partner in the Philadelphia office following three years as the general counsel of a national, publicly traded, physician practice management company.
In the last few years alone, Mr. Lebovitz has advised on a wide range of transactions, including:
- FS Investment Corporation, FS Energy & Power Fund, FS Investment Corporation II, FS Investment Corporation III, and FS Investment Corporation IV, five business development companies, in connection with their continuous offerings of US$2.6 billion, US$1.5 billion, US$2 billion, US$4 billion and US$2.6 billion, respectively, of their common stock.
- Adolor Corporation, a biotechnology company, in its US$415 million sale to Cubist Pharmaceuticals Inc., which included an innovative contingent payment right valued at up to US$225 million. Previously advised Adolor on its initial public offering and subsequent follow-on offerings of common stock as well as M&A transactions and general corporate matters.
- Underwriters, led by Stifel and Lazard Capital Markets, in connection with the initial public offering of common stock by Aratana Therapeutics, Inc., a biopharmaceutical company focused on animal health.
- Covance Inc., a leading clinical research organization (CRO) providing drug development services, in its: US$2.2 billion ten-year strategic alliance with Sanofi-Aventis and its related US$25 million acquisition of Sanofi’s research and development sites in Porcheville, France and Alnwick in the United Kingdom, US$1.6 billion ten-year strategic alliance with Eli Lilly and Company, and its acquisition of the Gene Expression Laboratory from Merck.
- Schramm, Inc., a manufacturer and global supplier to the hydraulic drill industry, in its acquisition by members of company management and private equity firm GenNx360 Capital Partners.
- HFF, Inc., a commercial real estate capital intermediary, in its US$257 million initial public offering of Class A common stock and secondary offerings of common stock.
- Bravo Brio Restaurant Group, Inc., an owner and operator of Italian restaurant brands, in its US$161 million initial public offering of common stock and its US$74 million secondary public offering.
- A multinational banking and financial services company in numerous capital markets transactions in the life sciences sector, including offerings for Emergent BioSolutions Inc., Savient Pharmaceuticals, Inc., Altair Nanotechnologies, Barrier Therapeutics, Inc., ArQule, Inc. and Bioenvision, Inc.
- Universal Business Payment Solutions Acquisition Corporation, a special purpose acquisition company (SPAC), in its US$72 million initial public offering of common stock, and subsequent acquisition of two operating companies, Jet Pay, a real-time card and ACH processor as well as merchant account provider, and A D Computer, a comprehensive payroll and tax filing service.
- Leerink Swann LLC and Cowen and Company, LLC as underwriters in connection with a US$57 million primary offering of common stock by Amicus Therapeutics, Inc., representing the second takedown from the Amicus’s shelf registration statement for which Mr. Lebovitz served as counsel to the investment banks.
- Florida Health Plan Administrators, LLC, the owner of Vista Healthplans, a private, Florida-based diversified health plan serving approximately 295,000 members, in its US$685 million sale to Coventry Health Care.
Yale College, B.A., 1979, Editor-in-chief of the Yale Daily News
University of Virginia School of Law, J.D., 1982, Notes Editor of The Virginia Journal of International Law
University of Cambridge, LL.M., 1983
Mr. Lebovitz is a trustee of Choate Rosemary Hall. Mr. Lebovitz is a former trustee of the Philadelphia Museum of Art, Rhody Squash and The Baldwin School and is a past president and current member of the Board of Trustees of the Samuel S. Fleisher Art Memorial.